Day: May 7, 2024

Nørresundby, Denmark, 7 May 2024Announcement no. 25/2024Q2 MEETS EXPECTATIONS, WITH GROWING ORDERS AND SALES, IN A MARKET, WHERE CUSTOMER INVENTORIES ARE NORMALIZING AND REORDERING IS BEGINNING TO PICK UP. “The results for Q2 are in line with our expectations for the quarter, reaching sales of DKK 125 million and trimming inventory by DKK 8 million during the quarter. In Q2, we furthermore see an increase in our order intake, indicating a shift towards more typical market dynamics, characterized by shorter order horizons and priority on inventory reductions. 2023/24 is indeed a challenging year for RTX, and in Q2 we have seen business gradually improving. We expect improvements to continue in the coming quarters, and despite some uncertainty we maintain our outlook for the year, as previously communicated in the 2022/23 annual report.”...

CINCINNATI, May 07, 2024 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, reported financial results for the thirteen weeks ended March 30, 2024. First Quarter 2024 Highlights (Thirteen weeks ended March 30, 2024)Net sales increased 0.2% to $350.3 million compared to $349.7 million in the prior year quarter Net loss totaled $(1.5) million, or $(0.01) per diluted share, compared to net loss of $(9.1) million, or $(0.05) per diluted share, in the prior year quarter Adjusted diluted EPS1 was $0.10 per diluted share compared to $0.06 per diluted share in the prior year quarter Adjusted EBITDA1 totaled $52.3 million compared to $40.2 million in the prior year quarter Net cash provided by operating activities was $11.7 million...

LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024. “iSpecimen made tremendous progress during the first quarter advancing our most promising operational initiative, Next Day Quotes, a program that expedites the biospecimen transaction process, which has helped elevate our market position and is expected to contribute meaningfully to our growth in 2024 and beyond,” said Tracy Curley, CEO of iSpecimen. “To transition our suppliers to Next Day Quotes, we have strategically refined our supplier network, deeply aligning and effectively...

– Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 –– SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants – PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “During the first few months of 2024, we completed enrollment of 130 adults with mild-to-moderate dementia with Lewy bodies (DLB) in the Phase 2 SHIMMER study, exceeding our target. In addition, we are preparing for the analysis of topline results from the Phase 2 SHINE study in mild-to-moderate Alzheimer’s disease,”...

Record Q1 Revenue of $73.6 Million; Y/Y Revenue Growth Accelerates for Second Consecutive Quarter Q1 GAAP Net Income Reaches $34.2 Million and Adj. EBITDA Increases to $13.2 Million Dave Raises 2024 Adjusted EBITDA Guidance to $30-$40 Million LOS ANGELES, May 07, 2024 (GLOBE NEWSWIRE) — Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE), one of the nation’s leading neobanks, today reported its financial results for the first quarter ended March 31, 2024. “2024 is off to a strong start as we exceeded growth and profitability expectations in the first quarter,” said Jason Wilk, Founder and CEO of Dave. “Member acquisition remained strong and efficient in spite of seasonal softness associated with tax refund season, and member retention expanded meaningfully which collectively drove 14% year-over-year growth in our monthly transacting...

MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 HighlightsFirst quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first quarter 2023 U.S. treatment session revenue increased by 22% versus the first quarter of 2023 U.S. NeuroStar Advanced Therapy system revenue of $3.3 million, in the quarter; the Company shipped 41 systemsRecent Operational and Marketing HighlightsNeuroStar Advanced Therapy received FDA clearance as a first line, adjunct treatment...

CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024 CAPLYTA total prescriptions increased 39%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance reiterated at $645 – $675 million Announced robust positive Phase 3 results from Study 501 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive disorder (MDD) NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2024 and provided...

Raises Full Year 2024 Guidance BRENTWOOD, Tenn., May 07, 2024 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2024.Revenues increased 7.7% to $717.4 million compared to the prior year periodSame-facility revenues increased 10.2%Net loss attributable to Surgery Partners, Inc. was $12.4 millionAdjusted EBITDA was $97.5 million, representing 8.2% growth compared to the prior year periodAdjusted EBITDA margin improved year-over-year to 13.6% Full year guidance raised to at least $3.05 billion in revenue and at least $505 million in Adjusted EBITDAWayne DeVeydt, Executive Chairman of the Board of Surgery Partners, noted, “We...